Efficacy of add-on montelukast in patients with non-controlled asthma: A Belgian open-label study

Current Medical Research and Opinion

Volumn 25, Issue 2, 2009, Pages 489-497

  Korn, Dana ^a,g   Van Den Brande, Paul ^b   Potvin, Emmanuel ^c   Dramaix, Michèle ^d   Herbots, Ella ^e   Peché, Rudi ^f  

^a BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

^b AZ St Maarten ^*  (Belgium)

^c Department of Respiratory Diseases   (Belgium)

^d UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^e Merck Sharp and Dohme   (Belgium)

^f Department of Respiratory Diseases   (Belgium)

^g Cliniques de l'Europe   (Belgium)

Author keywords

Allergic rhinitis; Asthma; Fixed associations; Montelukast

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; MONTELUKAST; ACETIC ACID DERIVATIVE; ANDROSTANE DERIVATIVE; ANTIASTHMATIC AGENT; BUDESONIDE; DRUG DERIVATIVE; ETHANOLAMINE DERIVATIVE; FLUTICASONE; FORMOTEROL; QUINOLINE DERIVATIVE; SALBUTAMOL; SALMETEROL;

ADD ON THERAPY; ADOLESCENT; ALLERGIC RHINITIS; ASTHMA; BELGIUM; CLINICAL TRIAL; CONFERENCE PAPER; CORRELATION ANALYSIS; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HUMAN; JUNIPER ASTHMA CONTROL QUESTIONNAIRE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; QUESTIONNAIRE; ADULT; ARTICLE; DRUG COMBINATION; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY;

ACETATES; ADULT; ALBUTEROL; ANDROSTADIENES; ANTI-ASTHMATIC AGENTS; ASTHMA; BELGIUM; BUDESONIDE; DRUG THERAPY, COMBINATION; ETHANOLAMINES; FEMALE; HUMANS; MALE; MIDDLE AGED; QUESTIONNAIRES; QUINOLINES;

EID: 64249140278     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990802667937     Document Type: Conference Paper

References (42)

1. Masoli M, Fabian D, Holt S, et al. Global burden of asthma. May 2004. Available from: http://www.ginasthma.com/ReportItem.asp?l1=2&l2=2&intId= 94 (accessed 28 July 2008)
2. Busse WW. Inflammation in asthma: the cornerstone of the disease and the target of therapy. J Allergy Clin Immunol 1998;102:S17-22 (Pubitemid 28487922)
3. Holgate ST. Pathogenesis of asthma. Clin Exp Allergy 2008;38:872-897
4. Fireman P. Understanding asthma pathophysiology. Allergy Asthma Proc 2003;24:79-83 (Pubitemid 37034191)
5. Global Initiative for Asthma. Global strategy for asthma management and prevention 2007. Available from: http://www.ginasthma.org (accessed 28 July 2008)
6. Bateman ED, Boushey HA, Bouquet J, et al. Can guideline-defined asthma control be achieved? The gaining optimal asthma control study. Am J Respir Crit Care Med 2004;170:836-844 (Pubitemid 39346477)
7. Malonne H, Lachman A, Van den Brande P. Impact of montelukast on symptoms in mild-to-moderate persistent asthma and exercise induced asthma: results of the ASTHMA survey. Curr Med Res Opin 2002;18:512-519 (Pubitemid 36133054)
8. Louis R, Lau LC, Bron AO, et al. The relationship between airways inflammation and asthma severity. Am J Respir Crit Care Med 2000;161:9-16 (Pubitemid 30055896)
9. Barnes PJ. Efficacy of inhaled corticosteroids in asthma. J Allergy Clin Immunol 1998;102:531-538 (Pubitemid 28487927)
10. Bisgaard H. Pathophysiology of the cysteinyl leukotrienes and effects of leukotriene receptor antagonists in asthma. Allergy 2001;56(Suppl 66):7-11 (Pubitemid 32538888)
11. Dworski R, Fitzgerald GA, Oates JA, et al. Effect of oral prednisone on airway inflammatory mediators in atopic asthma. Am J Respir Crit Care Med 1994;149:953-959 (Pubitemid 24108488)
12. Peters-Golden M, Sampson AP. Cysteinyl leukotriene interactions with other mediators and with glucocorticosteroids during airway inflammation. J Allergy Clin Immunol 2003;111(1 Suppl):S37-42 (Pubitemid 36135510)
13. Joos S, Miksch A, Szecsenyi J, et al. Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review. Thorax 2008;63:453-462 (Pubitemid 351698876)
14. Holgate ST, Peters-Golden M, Panettieri RA, et al. Roles of cysteinyl leukotrienes in airway inflammation, smooth muscle function, and remodeling. J Allergy Clin Immunol 2003;111(1 Suppl):S18-34 (Pubitemid 36135509)
15. 2- agonists: addition of montelukast in an open-label pilot study. Curr Med Res Opin 2005;21:863-869
16. Bjermer L, Bisgaard H, Bousquet J, et al. Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomized, comparative trial: IMPACT. BMJ 2003;327:891-895 (Pubitemid 37289961)
17. Vaquerizo MJ, Casan P, Castillo J, et al. Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma: CASIOPEA. Thorax 2003;58:204-210 (Pubitemid 36307997)
18. Price DB, Hernandez D, Magyar P, et al. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax 2003;58:211-216 (Pubitemid 36307998)
19. Lipworth B, Jackson C. Second-line controller therapy for persistent asthma uncontrolled on inhaled corticosteroids: the step 3 dilemma. Drugs 2002;62:2315-2332 (Pubitemid 35316383)
20. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008;63(Suppl 86):8-160
21. Magnan A, Fourre-Jullian C, Jullian H, et al. Rhinitis alone or rhinitis plus asthma: what makes the difference? Eur Respir J 1998;12:1073-1078
22. Price D, Zhang Q, Kocevar VS, et al. Effect of a concomitant diagnosis of allergic rhinitis on asthma-related health care use by adults. Clin Exp Allergy 2005;35:282-287 (Pubitemid 40516652)
23. Bousquet J and the ARIA Workshop Group. Management of Allergic Rhinitis and its Impact on Asthma (ARIA) Pocket Guide. A Pocket Guide for Physicians and Nurses. 2001. J Allergy Clin Immunol 2001;108:S147-334
24. Settipane RJ, Hagy GW, Settipane GA. Long-term risk factors for developing asthma and allergic rhinitis: a 23-years follow-up study of college students. Allergy Proc 1994;15:21-25 (Pubitemid 2050501)
25. Bousquet J, Gaugris S, Kocevar VS, et al. Increased risk of asthma attacks and emergency visits among asthma patients with allergic rhinitis: a subgroup analysis of the investigation of montelukast as a partner agent for complementary therapy. Clin Exp Allergy 2005;35:723-727 (Pubitemid 40961343)
26. Casale TB, Amin BV. Allergic rhinitis/asthma interrelationships. Clin Rev Allergy Immunol 2001;21:27-49 (Pubitemid 32620007)
27. Kay AB. Allergy and allergic diseases. First of two parts. N Engl J Med 2001;344:30-37
28. Gaga M, Lambrou P, Papageorgiou N, et al. Eosinophils are a feature of upper and lower airway pathology in non-atopic asthma, irrespective of the presence of rhinitis. Clin Exp Allergy 2000;30:663-669 (Pubitemid 30305629)
29. Braunstahl GJ, Kleinjan A, Overbeek SE, et al. Segmental bronchial provocation induces nasal inflammation in allergic rhinitis patients. Am J Respir Crit Care Med 2000;161:2051-2057 (Pubitemid 30418150)
30. Varner AE, Lemanske RF Jr. In: Asthma and Rhinitis, 2nd edn. Oxford: Blackwell Science, 2000:1172-1185
31. Togias A. Unique mechanistic features of allergic rhinitis. J Allergy Clin Immunol 2000;105(6 pt 2):S599-604 (Pubitemid 30399793)
32. Vignola AM, Chanez P, Godard P, et al. Relationship between rhinitis and asthma. Allergy 1998;53:833-839
33. Meltzer EO. Role for cysteinyl leukotriene receptor antagonist therapy in asthma and their potential role in allergic rhinitis base don the concept of "one linked airway disease". Ann Allergy Asthma Immunol 2000;84:176-185
34. Borderias L, Mincewicz G, Paggiaro PL, et al. Asthma control in patients with asthma and allergic rhinitis receiving add-on montelukast therapy for 12 months: a retrospective observational study. Curr Med Res Opin 2007;23:721-730 (Pubitemid 46631475)
35. Juniper EF, O'Byrne PM, Guyatt GH, et al. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999;14:902-907 (Pubitemid 29519356)
36. Juniper EF, Svensson K, Mörk AC, Ståhl E. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med. 2005;99:553-558 (Pubitemid 40468501)
37. Juniper EF, Bousquet J, Abetz L, et al.; GOAL Committee. Identifying 'well-controlled' and 'not well-controlled' asthma using the Asthma Control Questionnaire. Respir Med 2006;100:616-621
38. Partridge MR, van der Molen T, Myrseth SE, et al. Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm Med 2006;6:13 (Pubitemid 43984043)
39. Storms W. Update on montelukast and its role in the treatment of asthma, allergic rhinitis and exercise-induced bronchoconstriction. Expert Opin Pharmacother 2007;8:2173-2187 (Pubitemid 47505591)
40. Philip G, Nayak AS, Berger WE, et al. The effect of montelukast on rhinitis symptoms in patients with asthma and seasonal allergic rhinitis. Curr Med Res Opin 2004;20:1549-1558 (Pubitemid 39457543)
41. Virchow JC, Bachert C. Efficacy and safety of montelukast in adults with asthma and allergic rhinitis. Respir Med 2006;100:1952-1959 (Pubitemid 44490289)
42. Price DB, Swern A, Tozzi CA, et al. Effect of montelukast on lung function in asthma patients with allergic rhinitis: analysis from the COMPACT trial. Allergy 2006;61:737-742 (Pubitemid 43801409)